Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis

Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis - Efficacy of inhaled N-acetylcysteine in IPF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016706

Enrollment

Registered

2015-03-04

Start date

2013-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis

Interventions

N-acetylcysteine was administered by inhalation at the dose of 352.4 mg b.i.d. via an ultrasonic nebulizer.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The diagnosis of IPF and inclusion of subjects in the present study were based on the following criteria: an usual interstitial pneumonia (UIP) pattern or possible UIP pattern on high-resolution CT in accordance with the 2011 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American thoracic Association official statement on IPF.

Exclusion criteria

Exclusion criteria: The exclusion of other clinically known causes of UIP such as drug-induced pneumonitis, collagen vascular diseases, and hypersensitivity pneumonitis.

Design outcomes

Primary

Measure	Time frame
An absolute change in FVC at week 26 after the initiation of N-acetylcysteine therapy.	—

Countries

Japan

Contacts

Public ContactRyo Okuda

Saitama Red Cross Hospital Respiratory medicine

b980013@yahoo.co.jp048-852-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026